Skip to content

Welcome to Discover Pharma! Today is : November 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Executive Leadership

  • Biotech & Pharma Business,Pharmaceuticals and therapeutics

    Aspargo Labs appoints Sam Backenroth as chief financial officer to strengthen corporate and capital markets leadership

    Aspargo Labs, Inc., a pharmaceutical company commercializing a highly absorbent [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Abzena appoints Geoffrey Glass as CEO to drive next growth phase

    Abzena, the integrated CDMO and CRO specializing in complex biologics [...]

    May 5, 2026
  • Biotech & Pharma Business

    Creyon Bio appoints Serge Messerlian as CEO to advance AI-driven oligonucleotide drug development

    May 5, 2026
  • Biotech & Pharma Business

    Terumo BCT appoints Patrick Daly as chief business officer to drive unified growth strategy

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Polaryx Therapeutics activates first clinical trial site for SOTERIA Phase 2 basket trial of PLX-200
    Categories: Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Biogen partners with TRIMTECH on neurodegenerative disease protein degraders
    Categories: Biotech & Pharma Business, Central Nervous System, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Axoltis reports further Phase 2 data for ALS drug candidate NX210c
    Categories: Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top